ATE245993T1 - Allosterische modulatoren des nmda-rezeptors - Google Patents
Allosterische modulatoren des nmda-rezeptorsInfo
- Publication number
- ATE245993T1 ATE245993T1 AT95936300T AT95936300T ATE245993T1 AT E245993 T1 ATE245993 T1 AT E245993T1 AT 95936300 T AT95936300 T AT 95936300T AT 95936300 T AT95936300 T AT 95936300T AT E245993 T1 ATE245993 T1 AT E245993T1
- Authority
- AT
- Austria
- Prior art keywords
- nmda receptor
- allosteric modulators
- compositions
- methods
- receptor function
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 3
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 101710191405 Conantokin-G Proteins 0.000 abstract 1
- HTBKFGWATIYCSF-QGXIKSNHSA-N conantokin g Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN HTBKFGWATIYCSF-QGXIKSNHSA-N 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/323,436 US5830998A (en) | 1992-09-28 | 1994-10-14 | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US08/413,490 US5854217A (en) | 1992-09-28 | 1995-03-30 | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| PCT/US1995/013037 WO1996011698A1 (en) | 1994-10-14 | 1995-10-13 | Allosteric modulators of the nmda receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE245993T1 true ATE245993T1 (de) | 2003-08-15 |
Family
ID=26983959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95936300T ATE245993T1 (de) | 1994-10-14 | 1995-10-13 | Allosterische modulatoren des nmda-rezeptors |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US5854217A (de) |
| EP (1) | EP0785793B1 (de) |
| JP (1) | JP3273792B2 (de) |
| AT (1) | ATE245993T1 (de) |
| CA (1) | CA2202513C (de) |
| DE (1) | DE69531403D1 (de) |
| WO (1) | WO1996011698A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854217A (en) * | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US5763393A (en) * | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US6172041B1 (en) | 1996-07-22 | 2001-01-09 | University Of Utah Research Foundation | Use of conantokins |
| CA2261568A1 (en) * | 1996-07-22 | 1998-01-29 | University Of Utah Research Foundation | Conantokins |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6063819A (en) * | 1997-02-21 | 2000-05-16 | Cypros Pharmaceutical Corp. | Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels |
| US5844077A (en) * | 1997-04-28 | 1998-12-01 | Cytotherapeutics, Inc. | Use of conantokins for producing analgesia or for neuroprotection |
| CA2320032A1 (en) | 1998-02-10 | 1999-08-12 | University Of Utah Research Foundation | Methods for purifying and assaying a conus .gamma.-carboxylase |
| JP2003508091A (ja) * | 1999-09-10 | 2003-03-04 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | ガンマ−カルボキシグルタメート含有コノペプチド |
| US6399574B1 (en) | 2000-03-22 | 2002-06-04 | University Of Utah Research Foundation | Use of conantokins |
| EP1695703B1 (de) * | 2000-08-25 | 2010-08-11 | Research Corporation Technologies, Inc. | Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen |
| WO2002072005A2 (en) * | 2001-03-07 | 2002-09-19 | University Of Utah Research Foundation | Linear y-carboxyglutamate rich conotoxins |
| WO2002078629A2 (en) * | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US20070197583A1 (en) * | 2002-03-29 | 2007-08-23 | Welsh Michael J | Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction |
| US20030186860A1 (en) * | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2002952993A0 (en) | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
| AU2003901325A0 (en) | 2003-03-21 | 2003-04-03 | Stephen Locarnini | Therapeutic, prophylactic and diagnostic agents |
| EP1667516A4 (de) | 2003-08-29 | 2009-11-11 | Inst Medical W & E Hall | Verfahren zur auswahl von tiermodellen von tieren, die mutagenese unterzogen worden sind, und verwendung von myb-transkriptionsfaktoren zum screening |
| US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| NZ547767A (en) | 2003-12-24 | 2010-05-28 | Inst Medical W & E Hall | Therapeutic agents and uses therefor |
| JP4980211B2 (ja) | 2004-05-12 | 2012-07-18 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 細胞単離方法 |
| DK2407484T3 (en) | 2005-06-24 | 2016-09-05 | The Walter And Eliza Hall Inst Of Medical Res | Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those |
| CN100341566C (zh) * | 2005-12-29 | 2007-10-10 | 中国人民解放军军事医学科学院生物工程研究所 | 芋螺多肽衍生物用于制备戒毒药物的用途 |
| JP2009523739A (ja) | 2006-01-20 | 2009-06-25 | ウィメンズ アンド チルドレンズ ヘルス リサーチ インスティテュート インコーポレーティッド | 骨の病変の処置、予防、および診断の方法 |
| WO2008011006A2 (en) | 2006-07-18 | 2008-01-24 | University Of Utah Research Foundation | Methods for treating pain and screening analgesic compounds |
| US20090291150A1 (en) * | 2008-05-21 | 2009-11-26 | University Of Iowa Research Foundation | Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity |
| BRPI0902039B8 (pt) | 2009-06-09 | 2021-05-25 | Anhanguera Educacional Ltda | composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais |
| EP2260864A1 (de) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutische Anwendungen |
| CA2803029A1 (en) | 2010-06-23 | 2011-12-29 | Monash University | Constrained immunogenic compositions and uses therefor |
| US9079950B2 (en) | 2010-08-04 | 2015-07-14 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified Hepatitis C virus proteins |
| CN103533956A (zh) | 2010-11-26 | 2014-01-22 | 麦克法兰博尼特医学健康研究公司 | 组合物及其制备方法 |
| JP6681826B2 (ja) | 2013-05-31 | 2020-04-15 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | コノトキシンペプチド、医薬組成物およびそれらの使用 |
| WO2016149248A1 (en) | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
| US10111554B2 (en) | 2015-03-20 | 2018-10-30 | Meltz, LLC | Systems for and methods of controlled liquid food or beverage product creation |
| US10314320B2 (en) | 2015-03-20 | 2019-06-11 | Meltz, LLC | Systems for controlled liquid food or beverage product creation |
| AU2016345063B2 (en) | 2015-10-27 | 2021-08-05 | The Council Of The Queensland Institute Of Medical Research | A method of treatment and agents useful for same |
| US10689418B2 (en) * | 2015-12-22 | 2020-06-23 | Universidad Nacional De Colombia | Synthetic peptides that modulate the NMDA receptor |
| AU2017341671A1 (en) | 2016-10-12 | 2019-05-23 | Glycosynnovations Pty Ltd | Therapeutic agents and methods of producing same |
| JP7097900B2 (ja) * | 2016-10-20 | 2022-07-08 | メンファシス リミテッド | 電気泳動デバイス |
| WO2018200922A1 (en) | 2017-04-27 | 2018-11-01 | Meltz, LLC | Method for centrifugal extraction and apparatus suitable for carrying out this method |
| US11724849B2 (en) | 2019-06-07 | 2023-08-15 | Cometeer, Inc. | Packaging and method for single serve beverage product |
| EP4085066A4 (de) | 2020-01-05 | 2023-09-27 | Technion Research & Development Foundation Limited | Conus-basierte toxin-peptide, dafür codierende nukleinsäuren und verwendungen davon zum modulieren von nmda-rezeptoren |
| PH12022551856A1 (en) | 2020-01-22 | 2024-01-03 | Seelos Therapeutics Inc | Reducing side effects of nmda antagonists |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051413A (en) | 1986-02-13 | 1991-09-24 | Ciba-Geigy Corporation | Unsaturated amino acids |
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US5049555A (en) | 1988-12-19 | 1991-09-17 | Nova Pharmaceutical Corporation | Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics |
| US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US6017957A (en) * | 1989-08-08 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
| US5051403A (en) * | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
| US5559095A (en) * | 1989-11-22 | 1996-09-24 | Neurex Corporation | Delayed treatment method of reducing ischemia-related neuronal damage |
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| GB9109007D0 (en) | 1991-04-26 | 1991-06-12 | Merck Sharp & Dohme | Therapeutic method |
| DE69224069T2 (de) | 1991-09-09 | 1998-07-02 | Warner-Lambert Co., Ann Arbor, Mich. | Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält |
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| JPH07505908A (ja) * | 1992-09-28 | 1995-06-29 | マックセチーニ、マリア ルイザ | Ｎｍｄａ受容体のアロステリックモジュレーター |
| US5428069A (en) | 1993-01-11 | 1995-06-27 | The United States Of America As Represented By The Department Of Health & Human Services | Treating cognition with, aminocyclopropanecarboxylic derivatives |
| US5432155A (en) | 1993-06-29 | 1995-07-11 | The Salk Institute For Biological Studies | Conotoxins I |
| US5523323A (en) * | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| DE19543478A1 (de) * | 1995-11-22 | 1997-05-28 | Bayer Ag | Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman |
| US6172041B1 (en) * | 1996-07-22 | 2001-01-09 | University Of Utah Research Foundation | Use of conantokins |
| US5844077A (en) * | 1997-04-28 | 1998-12-01 | Cytotherapeutics, Inc. | Use of conantokins for producing analgesia or for neuroprotection |
-
1995
- 1995-03-30 US US08/413,490 patent/US5854217A/en not_active Expired - Fee Related
- 1995-10-13 WO PCT/US1995/013037 patent/WO1996011698A1/en not_active Ceased
- 1995-10-13 EP EP95936300A patent/EP0785793B1/de not_active Expired - Lifetime
- 1995-10-13 AT AT95936300T patent/ATE245993T1/de not_active IP Right Cessation
- 1995-10-13 JP JP51336396A patent/JP3273792B2/ja not_active Expired - Fee Related
- 1995-10-13 CA CA002202513A patent/CA2202513C/en not_active Expired - Fee Related
- 1995-10-13 DE DE69531403T patent/DE69531403D1/de not_active Expired - Lifetime
-
1998
- 1998-09-03 US US09/146,269 patent/US6110894A/en not_active Expired - Fee Related
- 1998-09-03 US US09/146,268 patent/US6284731B1/en not_active Expired - Fee Related
-
2000
- 2000-04-20 US US09/553,042 patent/US6511963B1/en not_active Expired - Fee Related
-
2002
- 2002-11-25 US US10/302,971 patent/US20030134799A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10504316A (ja) | 1998-04-28 |
| EP0785793A4 (de) | 2000-08-30 |
| US6110894A (en) | 2000-08-29 |
| DE69531403D1 (de) | 2003-09-04 |
| US6511963B1 (en) | 2003-01-28 |
| US6284731B1 (en) | 2001-09-04 |
| JP3273792B2 (ja) | 2002-04-15 |
| CA2202513A1 (en) | 1996-04-25 |
| EP0785793A1 (de) | 1997-07-30 |
| CA2202513C (en) | 2002-08-13 |
| EP0785793B1 (de) | 2003-07-30 |
| WO1996011698A1 (en) | 1996-04-25 |
| US20030134799A1 (en) | 2003-07-17 |
| US5854217A (en) | 1998-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69531403D1 (de) | Allosterische modulatoren des nmda-rezeptors | |
| NO986100L (no) | Androgene reseptormodulerende forbindelser og fremgangsmÕter | |
| BR9510486A (pt) | Compostos moduladores de receptores de esteróide e métodos | |
| MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
| EP0911321A3 (de) | Verbindungen zur Behandlung von Osteoporose | |
| MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| FI20051271L (fi) | Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| DK0841928T3 (da) | Sustained release-formulering af d-threo-methylphenidat | |
| AU2002345497A1 (en) | Cips as modifiers of the p53 pathway and method of use | |
| JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
| GB9712966D0 (en) | Novel chalcones | |
| BR9708347A (pt) | Compostos de tetrahidorbeta-carbonila | |
| DE69332605D1 (de) | Allosterische modulatoren des nmda-rezeptors | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| BR9714189A (pt) | N-(piridinilamino) isoindolinas e compostos relacionados | |
| ID27964A (id) | Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |